An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of hydroxychloroquine and chloroquine therapy.


Creative Commons License

Celotto S., Veronese N., Barbagallo M., Ometto F., Smith L., Pardhan S., ...More

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, vol.103, pp.599-606, 2021 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 103
  • Publication Date: 2021
  • Doi Number: 10.1016/j.ijid.2020.12.018
  • Journal Name: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • Journal Indexes: Science Citation Index Expanded, Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.599-606
  • Keywords: Hydroxychloroquine, Chloroquine, COVID-19, umbrella review, EULAR RECOMMENDATIONS, RHEUMATOID-ARTHRITIS, LUPUS-ERYTHEMATOSUS, HEALTH, DRUGS, RISK, MANAGEMENT, PREGNANCY, DISEASE, EXCESS

Abstract

BACKGROUND & AIMS: Hydroxychloroquine (HCQ) and chloroquine (CQ) are anti-malarial drugs frequently used in the rheumatologic field. They were recently identified as potential therapeutic options for Coronavirus Disease (COVID-19). The present study aims to map and grade the diverse health outcomes associated with HCQ/CQ using an umbrella review approach.